Cargando…

Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials

BACKGROUND: Symptoms are common among patients enrolled in phase I trials. We assessed the validity of Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) items in relation to previously validated assessments of quality of life and psychological distre...

Descripción completa

Detalles Bibliográficos
Autores principales: Sedhom, Ramy, Ferrell, Betty, Ruel, Nora, Koczywas, Marianna, Chung, Vincent, Smith, Thomas J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768928/
https://www.ncbi.nlm.nih.gov/pubmed/33392443
http://dx.doi.org/10.1093/jncics/pkaa067
_version_ 1783629234284003328
author Sedhom, Ramy
Ferrell, Betty
Ruel, Nora
Koczywas, Marianna
Chung, Vincent
Smith, Thomas J
author_facet Sedhom, Ramy
Ferrell, Betty
Ruel, Nora
Koczywas, Marianna
Chung, Vincent
Smith, Thomas J
author_sort Sedhom, Ramy
collection PubMed
description BACKGROUND: Symptoms are common among patients enrolled in phase I trials. We assessed the validity of Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) items in relation to previously validated assessments of quality of life and psychological distress. We used data from a randomized trial testing a palliative care support intervention for patients enrolled on phase I trials. METHODS: Patients (n = 479) were accrued to the parent study prior to initiating a phase I clinical trial with data collected at baseline, 4, and 12 weeks. We determined the correlation of PRO-CTCAE with distress level, Functional Assessment of Cancer Therapy - General (FACT-G) total, and subscale domain scores. RESULTS: Patients were predominantly female (56.8%) and older than age 60 years, and 30.7% were from minority populations. The correlation coefficient for distress level for all PRO-CTCAE items was small to moderate (Pearson r = 0.33-0.46). Pearson correlation coefficient for FACT-G total was moderate (r = -0.45 to -0.69). Stronger associations were noted for mood items of the PRO-CTCAE only (with distress level, r = 0.55-0.6; with FACT-G, r = -0.54 to -0.6). PRO-CTCAE symptom interference scores had the strongest correlation with distress level (Pearson r = 0.46) and FACT-G total (Pearson r = -0.69). Correlations between PRO-CTCAE items and corresponding FACT-G (total and subscales) and distress levels reached statistical significance for all items (P <.001). CONCLUSION: Evidence demonstrates validity of PRO-CTCAE in a heterogeneous US sample of patients undergoing cancer treatment on phase I trials, with small to moderate correlations with distress level for all PRO-CTCAE items and moderate correlations with quality of life as measured by FACT-G total.
format Online
Article
Text
id pubmed-7768928
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77689282020-12-31 Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials Sedhom, Ramy Ferrell, Betty Ruel, Nora Koczywas, Marianna Chung, Vincent Smith, Thomas J JNCI Cancer Spectr Article BACKGROUND: Symptoms are common among patients enrolled in phase I trials. We assessed the validity of Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) items in relation to previously validated assessments of quality of life and psychological distress. We used data from a randomized trial testing a palliative care support intervention for patients enrolled on phase I trials. METHODS: Patients (n = 479) were accrued to the parent study prior to initiating a phase I clinical trial with data collected at baseline, 4, and 12 weeks. We determined the correlation of PRO-CTCAE with distress level, Functional Assessment of Cancer Therapy - General (FACT-G) total, and subscale domain scores. RESULTS: Patients were predominantly female (56.8%) and older than age 60 years, and 30.7% were from minority populations. The correlation coefficient for distress level for all PRO-CTCAE items was small to moderate (Pearson r = 0.33-0.46). Pearson correlation coefficient for FACT-G total was moderate (r = -0.45 to -0.69). Stronger associations were noted for mood items of the PRO-CTCAE only (with distress level, r = 0.55-0.6; with FACT-G, r = -0.54 to -0.6). PRO-CTCAE symptom interference scores had the strongest correlation with distress level (Pearson r = 0.46) and FACT-G total (Pearson r = -0.69). Correlations between PRO-CTCAE items and corresponding FACT-G (total and subscales) and distress levels reached statistical significance for all items (P <.001). CONCLUSION: Evidence demonstrates validity of PRO-CTCAE in a heterogeneous US sample of patients undergoing cancer treatment on phase I trials, with small to moderate correlations with distress level for all PRO-CTCAE items and moderate correlations with quality of life as measured by FACT-G total. Oxford University Press 2020-08-14 /pmc/articles/PMC7768928/ /pubmed/33392443 http://dx.doi.org/10.1093/jncics/pkaa067 Text en © The Author(s) 2020. Published by Oxford University Press. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Sedhom, Ramy
Ferrell, Betty
Ruel, Nora
Koczywas, Marianna
Chung, Vincent
Smith, Thomas J
Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials
title Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials
title_full Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials
title_fullStr Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials
title_full_unstemmed Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials
title_short Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials
title_sort using patient-reported outcomes to describe the patient experience on phase i clinical trials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768928/
https://www.ncbi.nlm.nih.gov/pubmed/33392443
http://dx.doi.org/10.1093/jncics/pkaa067
work_keys_str_mv AT sedhomramy usingpatientreportedoutcomestodescribethepatientexperienceonphaseiclinicaltrials
AT ferrellbetty usingpatientreportedoutcomestodescribethepatientexperienceonphaseiclinicaltrials
AT ruelnora usingpatientreportedoutcomestodescribethepatientexperienceonphaseiclinicaltrials
AT koczywasmarianna usingpatientreportedoutcomestodescribethepatientexperienceonphaseiclinicaltrials
AT chungvincent usingpatientreportedoutcomestodescribethepatientexperienceonphaseiclinicaltrials
AT smiththomasj usingpatientreportedoutcomestodescribethepatientexperienceonphaseiclinicaltrials